To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Paul gets triple-A rating on royalties fund
New York-based Paul Capital Partners has securitised most of the assets in a $300m drug-royalty fund.
